Prevalence by Age and Predictors of Medullary Thyroid Cancer in Patients with Lower Risk Germline RET Proto-Oncogene Mutations-Reference-Cited by-同舟云学术

Prevalence by Age and Predictors of Medullary Thyroid Cancer in Patients with Lower Risk Germline RET Proto-Oncogene Mutations

Published:2014-07 Issue:7 Volume:24 Page:1096-1106
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Rich Thereasa A.¹²,Feng Lei³,Busaidy Naifa⁴,Cote Gilbert J.⁴,Gagel Robert F.⁴,Hu Mimi⁴,Jimenez Camilo⁴,Lee Jeffrey E.¹,Perrier Nancy¹,Sherman Steven I.⁴,Waguespack Steven G.⁴⁵,Ying Anita⁴⁵,Grubbs Elizabeth¹

Affiliation:

1. Department of Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas.

2. Clinical Cancer Genetics Program, MD Anderson Cancer Center, University of Texas, Houston, Texas.

3. Department of Biostatistics, MD Anderson Cancer Center, University of Texas, Houston, Texas.

4. Department of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, University of Texas, Houston, Texas.

5. Department of Pediatrics, MD Anderson Cancer Center, University of Texas, Houston, Texas.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2013.0620

Reference67 articles.

1. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A

2. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC

3. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours

4. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg RET mutation in an Israeli multicenter study;Frontiers in Endocrinology;2023-10-30

2. Medullary thyroid cancer with RET V804M mutation: more indolent than expected?;Surgery;2023-01

3. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2022-08

4. Controversy on the management of patients carrying RET p.V804M mutation;Endocrine;2021-10-12

5. Multiple endocrine neoplasia type 2: A review;Seminars in Cancer Biology;2021-04